A researcher proposes that ibogaine could work on a shared 'reward system' problem behind addiction, PTSD, OCD, and eating disorders — and says the idea still needs to be tested.
A 2025 hypothesis-and-theory paper — a proposal, not a study — arguing that ibogaine might act on a problem several conditions share in the brain's reward system, including PTSD.
This is a theory paper, not a study with new results. An independent researcher argues that several conditions usually treated as separate — addiction, PTSD, OCD, and eating disorders — may share a common disruption in the brain's reward system, and that ibogaine's effects on dopamine and glutamate signaling, its boost to a nerve-growth factor called GDNF, and the window of brain plasticity it opens could in principle help recalibrate that system. The author is explicit that, outside of addiction, there are no clinical ibogaine studies for these conditions yet — so this is a proposed mechanism to test, not a proven treatment. Ibogaine remains Schedule I in the United States and carries serious, documented cardiac risks (it can cause dangerous QT prolongation, and deaths have occurred without careful medical screening), so it is only appropriate in tightly controlled, monitored settings.
The paper's central hypothesis is that ibogaine's upregulation of the neurotrophic factor GDNF, its modulation of dopamine and glutamate signaling, and its reopening of a neuroplasticity window together could 'restore reward system fidelity.' The author argues that addiction, PTSD, OCD, and eating disorders — though diagnostically distinct — share disrupted reward circuitry, so a treatment acting on that shared dysfunction could cross diagnostic lines. For PTSD specifically, the paper points to reduced activity in reward regions (the VTA and nucleus accumbens) linked to anhedonia and emotional blunting.
This is a 'Hypothesis and Theory' article — a single-author synthesis and argument, not new data or a clinical trial. The mechanistic building blocks (GDNF, dopamine and glutamate, plasticity) draw on real preclinical and observational work, and the addiction signal rests largely on uncontrolled case series. But the transdiagnostic leap is explicitly the author's proposal: as he writes, 'with the exception of addiction, no clinical ibogaine studies currently exist for the disorders discussed.' He is appropriately cautious — 'claims of efficacy must remain provisional regardless of how promising early outcomes appear.' Read this as a well-argued research direction, not established treatment.
The framework connects to evidence we already track. The paper cites the Stanford magnesium-ibogaine (MISTIC) trial in Special Operations veterans with traumatic brain injury as early support, and PTSD sits at the center of its reward-system argument. That said, the veteran evidence remains a small, uncontrolled open-label trial, not proof — and ibogaine's serious cardiac risk and Schedule I status mean any real-world use belongs only in screened, medically supervised research settings.
A note on what this is: unlike most Field Notes, this entry covers a hypothesis-and-theory paper rather than a completed study. It proposes a mechanism and a set of testable predictions; it does not report new clinical results. We include it because it frames a serious, veteran-relevant research direction — but nothing here should be read as evidence that ibogaine treats PTSD or any other condition.
Read the full paper →